Stock MarketGoldman Sachs doubles down on stock market outlook for 20261 day agoThe S&P 500 has climbed to near-record highs despite growing concerns about valuations, AI spending, and signs of speculative behavior...
Stock Markete.l.f. Beauty, B&G Foods, and Celsius Shares Are Soaring, What You Need To Know2 days agoWhat Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release...
Stock MarketBank of America delivers uncomfortable message for stock market investors3 days agoThe stock market has been on a tremendous run, one that may simply be too good to last. Bank of...
CurrenciesGoldman Sachs sees rupee weakness capped after RBI’s steps to boost inflows | Finance News5 days ago By Subhadip Sircar The Indian rupee’s slide may be nearing a floor after authorities unveiled measures to...
Stock MarketGoldman Sachs CEO sends blunt message to stock market investors6 days agoDavid Solomon was asked about market conditions at the Economic Club of New York on June 2. He paused before...
Stock MarketGoldman Sachs Sees Two Risks Facing the Stock Market—Here’s What To Know2 weeks agoThe S&P 500 is on track to post its ninth straight week of gains, its longest streak since 2023.Credit: ANGELA...
Stock MarketHere’s what could pop the stock market bubble2 weeks agoIf something is going to unsettle the great bull market of 2026 soon, Goldman Sachs strategists have found two possible...
CurrenciesGoldman warns broader energy shock could strengthen dollar and weigh on Europe3 weeks agofistful of dollars ©Jonathan Cutrer Goldman Sachs strategists said the U.S. dollar may be gradually building upward pressure beneath the...
Stock MarketOpenAI Plans Confidential IPO: ChatGPT Maker Targets Stock Market Debut Amid Global AI Boom3 weeks agoOpenAI is preparing to confidentially file for an initial public offering (IPO) in the coming weeks, according to a report...
Stock MarketGoldman Sachs sets new Biogen stock price target on bold Alzheimer’s bet4 weeks agoBiogen (NASDAQ: BIIB) has had a rocky few years. Its multiple sclerosis franchise has been bleeding market share to generics...